200 related articles for article (PubMed ID: 21957304)
1. Adenovirus with hexon Tat-protein transduction domain modification exhibits increased therapeutic effect in experimental neuroblastoma and neuroendocrine tumors.
Yu D; Jin C; Leja J; Majdalani N; Nilsson B; Eriksson F; Essand M
J Virol; 2011 Dec; 85(24):13114-23. PubMed ID: 21957304
[TBL] [Abstract][Full Text] [Related]
2. Genetic incorporation of the protein transduction domain of Tat into Ad5 fiber enhances gene transfer efficacy.
Han T; Tang Y; Ugai H; Perry LE; Siegal GP; Contreras JL; Wu H
Virol J; 2007 Oct; 4():103. PubMed ID: 17958897
[TBL] [Abstract][Full Text] [Related]
3. Tropism and transduction of oncolytic adenovirus 5 vectors in cancer therapy: Focus on fiber chimerism and mosaicism, hexon and pIX.
Stepanenko AA; Chekhonin VP
Virus Res; 2018 Sep; 257():40-51. PubMed ID: 30125593
[TBL] [Abstract][Full Text] [Related]
4. Adenovirus serotype 5 vectors with Tat-PTD modified hexon and serotype 35 fiber show greatly enhanced transduction capacity of primary cell cultures.
Yu D; Jin C; Ramachandran M; Xu J; Nilsson B; Korsgren O; Le Blanc K; Uhrbom L; Forsberg-Nilsson K; Westermark B; Adamson R; Maitland N; Fan X; Essand M
PLoS One; 2013; 8(1):e54952. PubMed ID: 23372800
[TBL] [Abstract][Full Text] [Related]
5. Substitution of adenovirus serotype 3 hexon onto a serotype 5 oncolytic adenovirus reduces factor X binding, decreases liver tropism, and improves antitumor efficacy.
Short JJ; Rivera AA; Wu H; Walter MR; Yamamoto M; Mathis JM; Curiel DT
Mol Cancer Ther; 2010 Sep; 9(9):2536-44. PubMed ID: 20736345
[TBL] [Abstract][Full Text] [Related]
6. Enhanced antitumor efficacy of fiber-modified, midkine promoter-regulated oncolytic adenovirus in human malignant mesothelioma.
Takagi-Kimura M; Yamano T; Tamamoto A; Okamura N; Okamura H; Hashimoto-Tamaoki T; Tagawa M; Kasahara N; Kubo S
Cancer Sci; 2013 Nov; 104(11):1433-9. PubMed ID: 23962292
[TBL] [Abstract][Full Text] [Related]
7. Oncolytic adenovirus modified with somatostatin motifs for selective infection of neuroendocrine tumor cells.
Leja J; Yu D; Nilsson B; Gedda L; Zieba A; Hakkarainen T; Åkerström G; Öberg K; Giandomenico V; Essand M
Gene Ther; 2011 Nov; 18(11):1052-62. PubMed ID: 21490682
[TBL] [Abstract][Full Text] [Related]
8. Identification of coagulation factor (F)X binding sites on the adenovirus serotype 5 hexon: effect of mutagenesis on FX interactions and gene transfer.
Alba R; Bradshaw AC; Parker AL; Bhella D; Waddington SN; Nicklin SA; van Rooijen N; Custers J; Goudsmit J; Barouch DH; McVey JH; Baker AH
Blood; 2009 Jul; 114(5):965-71. PubMed ID: 19429866
[TBL] [Abstract][Full Text] [Related]
9. Protein transduction domains fused to virus receptors improve cellular virus uptake and enhance oncolysis by tumor-specific replicating vectors.
Kühnel F; Schulte B; Wirth T; Woller N; Schäfers S; Zender L; Manns M; Kubicka S
J Virol; 2004 Dec; 78(24):13743-54. PubMed ID: 15564483
[TBL] [Abstract][Full Text] [Related]
10. Tat-PTD-modified oncolytic adenovirus driven by the SCG3 promoter and ASH1 enhancer for neuroblastoma therapy.
Jin C; Yu D; Čančer M; Nilsson B; Leja J; Essand M
Hum Gene Ther; 2013 Aug; 24(8):766-75. PubMed ID: 23889332
[TBL] [Abstract][Full Text] [Related]
11. Genetic strategy to decrease complement activation with adenoviral therapies.
Gentile CM; Borovjagin AV; Richter JR; Jani AH; Wu H; Zinn KR; Warram JM
PLoS One; 2019; 14(4):e0215226. PubMed ID: 31026285
[TBL] [Abstract][Full Text] [Related]
12. A mosaic adenovirus possessing serotype Ad5 and serotype Ad3 knobs exhibits expanded tropism.
Takayama K; Reynolds PN; Short JJ; Kawakami Y; Adachi Y; Glasgow JN; Rots MG; Krasnykh V; Douglas JT; Curiel DT
Virology; 2003 May; 309(2):282-93. PubMed ID: 12758175
[TBL] [Abstract][Full Text] [Related]
13. Adenovirus serotype 30 fiber does not mediate transduction via the coxsackie-adenovirus receptor.
Law LK; Davidson BL
J Virol; 2002 Jan; 76(2):656-61. PubMed ID: 11752156
[TBL] [Abstract][Full Text] [Related]
14. Expanded anticancer therapeutic window of hexon-modified oncolytic adenovirus.
Shashkova EV; May SM; Doronin K; Barry MA
Mol Ther; 2009 Dec; 17(12):2121-30. PubMed ID: 19755961
[TBL] [Abstract][Full Text] [Related]
15. E1A, E1B double-restricted adenovirus with RGD-fiber modification exhibits enhanced oncolysis for CAR-deficient biliary cancers.
Wakayama M; Abei M; Kawashima R; Seo E; Fukuda K; Ugai H; Murata T; Tanaka N; Hyodo I; Hamada H; Yokoyama KK
Clin Cancer Res; 2007 May; 13(10):3043-50. PubMed ID: 17505007
[TBL] [Abstract][Full Text] [Related]
16. A mosaic fiber adenovirus serotype 5 vector containing reovirus sigma 1 and adenovirus serotype 3 knob fibers increases transduction in an ovarian cancer ex vivo system via a coxsackie and adenovirus receptor-independent pathway.
Tsuruta Y; Pereboeva L; Glasgow JN; Rein DT; Kawakami Y; Alvarez RD; Rocconi RP; Siegal GP; Dent P; Fisher PB; Curiel DT
Clin Cancer Res; 2007 May; 13(9):2777-83. PubMed ID: 17473211
[TBL] [Abstract][Full Text] [Related]
17. Improved adenovirus type 5 vector-mediated transduction of resistant cells by piggybacking on coxsackie B-adenovirus receptor-pseudotyped baculovirus.
Granio O; Porcherot M; Corjon S; Kitidee K; Henning P; Eljaafari A; Cimarelli A; Lindholm L; Miossec P; Boulanger P; Hong SS
J Virol; 2009 Jun; 83(12):6048-66. PubMed ID: 19357170
[TBL] [Abstract][Full Text] [Related]
18. Adenovirus serotype 5 hexon mediates liver gene transfer.
Waddington SN; McVey JH; Bhella D; Parker AL; Barker K; Atoda H; Pink R; Buckley SM; Greig JA; Denby L; Custers J; Morita T; Francischetti IM; Monteiro RQ; Barouch DH; van Rooijen N; Napoli C; Havenga MJ; Nicklin SA; Baker AH
Cell; 2008 Feb; 132(3):397-409. PubMed ID: 18267072
[TBL] [Abstract][Full Text] [Related]
19. Ad5/48 hexon oncolytic virus expressing sTGFβRIIFc produces reduced hepatic and systemic toxicities and inhibits prostate cancer bone metastases.
Xu W; Zhang Z; Yang Y; Hu Z; Wang CH; Morgan M; Wu Y; Hutten R; Xiao X; Stock S; Guise T; Prabhakar BS; Brendler C; Seth P
Mol Ther; 2014 Aug; 22(8):1504-1517. PubMed ID: 24791939
[TBL] [Abstract][Full Text] [Related]
20. Genetically modified adenoviral vector with the protein transduction domain of Tat improves gene transfer to CAR-deficient cells.
Liu S; Mao Q; Zhang W; Zheng X; Bian Y; Wang D; Li H; Chai L; Zhao J; Xia H
Biosci Rep; 2009 Apr; 29(2):103-9. PubMed ID: 18721127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
